Soligenix
NASDAQ: SNGXPrinceton, US · Delaware corporation · 1 known investors
Founders & leadership
RC
Richard C. Straube, MD MScExecutive
KK
Karen KrumeichExecutive
OD
Oreola Donini, PhDExecutive
CJ
Christopher J. Schaber, PhDExecutive
AT
Adam T. RumageNamed on SEC filing
RC
R. Christopher Cavalli, PhDNamed on SEC filing
MM
Marco M. Brughera, DVMNamed on SEC filing
Board
KL
Keith L. Brownlie, CPABoard director
JB
Jerome B. Zeldis, PhDBoard director
GA
Gregg A. LaPointe, CPABoard director
RJ
Robert J. Rubin, MDBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$2M disclosed across 1 round · 2017
▶$2MraisedNov 2017 · 6 investors · PharmaceuticalsRule 506(b)
▶$2MraisedNov 2017 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Adam T. RumageExecutive Officer
- Richard C. Straube, MD MScExecutive Officer
- Karen KrumeichExecutive Officer
- Oreola Donini, PhDExecutive Officer
- Keith L. Brownlie, CPADirector
- Jerome B. Zeldis, PhDDirector
- Gregg A. LaPointe, CPADirector
- Robert J. Rubin, MDDirector
- R. Christopher Cavalli, PhDExecutive Officer
- Marco M. Brughera, DVMDirector
- Christopher J. Schaber, PhDExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- Finders' fees
- $137.5K
- Placement agents
- Aegis Capital Corp.
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Soligenix for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 11 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $600K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $509.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $470.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $149.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- Who are Soligenix's investors?
- Soligenix's investors include Pontifax Venture Capital.
- How much funding has Soligenix raised?
- Soligenix has disclosed $2M raised across 1 round.
- Where is Soligenix headquartered?
- Soligenix is headquartered in Princeton, US.
